Core Viewpoint - Huadong Medicine's subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical, has received acceptance for the marketing authorization application of Roflumilast cream (ZORYVE®) 0.05%, aimed at treating mild to moderate atopic dermatitis in children aged 2 to 5, marking a significant milestone in the product's development and enhancing the company's competitive edge in autoimmune skin treatments [1][2]. Group 1: Product Development and Market Position - The active ingredient of ZORYVE® is Roflumilast, a highly selective non-steroidal phosphodiesterase-4 (PDE4) inhibitor that reduces inflammation by inhibiting the production of pro-inflammatory mediators [1]. - The cream is part of a collaboration with Arcutis Biotherapeutics, Inc., granting Huadong Medicine exclusive rights for development, registration, production, and commercialization in Greater China and Southeast Asia [1]. - The application targets a significant unmet need in the market, particularly for children aged 2 to 5, where treatment options are currently limited to traditional topical corticosteroids and calcineurin inhibitors [2]. Group 2: Market Demand and Clinical Need - There are approximately 67 million atopic dermatitis patients in China, indicating a substantial unmet clinical demand [2]. - The prevalence of atopic dermatitis in children aged 1 to 7 is reported at 12.94%, highlighting the urgent need for safe and effective treatment options for this age group [2]. - The acceptance of the 0.05% cream application is expected to provide new treatment options for pediatric patients, establishing a differentiated market barrier and first-mover advantage for Huadong Medicine in a competitive landscape [2]. Group 3: Broader Product Portfolio - Huadong Medicine has developed a differentiated product pipeline that includes various concentrations of Roflumilast cream, with higher concentrations (0.15% and 0.3%) also having received regulatory acceptance for treating older patients with atopic dermatitis and psoriasis [3]. - Additionally, a foam formulation of Roflumilast (ZORYVE®) 0.3% for seborrheic dermatitis in patients aged 9 and above is currently undergoing Phase III clinical trials [3].

Core Viewpoint - Huadong Medicine's subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical Co., has received acceptance for the marketing authorization application of Roflumilast cream (ZORYVE®) 0.05%, aimed at treating mild to moderate atopic dermatitis in children aged 2 to 5, marking a significant milestone in the product's development and enhancing the company's competitive edge in the autoimmune skin treatment sector [1][2]. Product Advantages - ZORYVE® contains Roflumilast, a highly selective non-steroidal phosphodiesterase-4 (PDE4) inhibitor that reduces inflammation by inhibiting the enzyme that increases pro-inflammatory mediators [2]. - The product was developed in collaboration with Arcutis Biotherapeutics, granting Huadong exclusive rights for development, registration, production, and commercialization in Greater China and Southeast Asia [2]. - Atopic dermatitis is a prevalent chronic inflammatory skin condition affecting both children and adults, with significant impacts on quality of life [2]. Market Demand - There are approximately 67 million atopic dermatitis patients in China, indicating a substantial unmet clinical need, particularly for children aged 1 to 7, with a prevalence rate of 12.94% [3]. - The introduction of Roflumilast cream addresses a clear gap in treatment options for children aged 2 to 5, who currently rely on traditional topical corticosteroids and calcineurin inhibitors [3]. - The cream's once-daily dosing regimen enhances treatment adherence, making it a more suitable option for young patients [3]. Strategic Development - Huadong Medicine is systematically introducing a range of Roflumilast products, including higher concentrations for older patients and other skin conditions, to establish a comprehensive presence in the autoimmune skin disease market [4]. - The company is focusing on a dual strategy of "introducing partnerships" and "independent innovation" to build a competitive product pipeline in autoimmune diseases, covering various conditions such as psoriasis and rheumatoid arthritis [5]. - Ongoing collaborations and clinical trials for other products further demonstrate the company's commitment to expanding its portfolio in the autoimmune sector [6]. Strategic Partnerships - In early 2026, Huadong Medicine deepened its strategic partnership with Denmark's MC2 Therapeutics to commercialize the Biomee® series in Greater China, enhancing its position in the topical skin treatment market [7]. - The acceptance of the Roflumilast cream application signifies the company's innovative capabilities and marks a phase of growth in the autoimmune skin disease field [7]. - With multiple differentiated product pipelines, Huadong Medicine aims to strengthen its influence in the multi-billion-dollar autoimmune market in China [7].

Core Viewpoint - Huadong Medicine's subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical, has received acceptance for the market approval application of ZORYVE® 0.15% cream for treating mild to moderate atopic dermatitis in patients aged 6 and above, marking a significant milestone in the product's development [1][4] Group 1: Product Development and Market Potential - The acceptance of the ZORYVE® 0.15% cream application signifies a critical advancement in Huadong Medicine's research and development process, enhancing its core competitiveness in the treatment of autoimmune skin diseases [1][4] - ZORYVE® is a non-steroidal phosphodiesterase-4 (PDE4) inhibitor, which helps reduce inflammation by inhibiting the enzyme that increases pro-inflammatory mediators [2] - The atopic dermatitis market in China is projected to grow significantly, with an estimated market size of approximately $970 million in 2022, expected to reach $7.07 billion by 2030, reflecting a compound annual growth rate (CAGR) of 28.2% [2] Group 2: Strategic Positioning and Product Portfolio - ZORYVE® has received full recognition from the FDA in the United States, with a mature product matrix covering multiple age groups and indications, including treatments for atopic dermatitis and psoriasis [3] - Huadong Medicine is focusing on autoimmune diseases as one of its three core development directions, continuously enhancing its product introduction and independent research and development capabilities [3] - The company has a comprehensive range of products and pipeline candidates addressing various autoimmune diseases, positioning itself as one of the most diversified pharmaceutical companies in this field in China [3]